The treatment of ACE2 knockout mice with Ang II infusion and recombinant ACE2 (rhACE2) eliminated ERK1/2, JAK2-STAT3, and PKC signaling by rhACE2 and was at least partially responsible for attenuation of Ang II−induced myocardial hypertrophy and fibrosis and improvement in diastolic dysfunction (33).